Apellis Pharmaceuticals (APLS) Gets a Hold From Mizuho Securities
Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan
Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $39 From $42
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
J.P. Morgan analyst Anupam Rama maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $64 to $57.According to TipRanks data, the analyst has a success
Sobi and Enable Injections Announce Agreement to Develop and Distribute Aspaveli in Combination With EnFuse in Sobi Territories
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $66 to $61.According to TipRanks data, the analyst has a